IL-7 contributes to the progression of human T-cell acute lymphoblastic leukemias

Cancer Research

Volumn 71, Issue 14, 2011, Pages 4780-4789

  Silva, Ana ^a,c   Laranjeira, Angelo B A ^d   Martins, Leila R ^a   Cardoso, Bruno A ^a   Demengeot, Jocelyne ^b   Andres Yunes J ^d   Seddon, Benedict ^c   Barata, João T ^a  

^a INSTITUTO DE MEDICINA MOLECULAR JOÃO LOBO ANTUNES   (Portugal)

^b INSTITUTO GULBENKIAN DE CIÊNCIA   (Portugal)

^c NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

^d CENTRO INFANTIL BOLDRINI   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1B; INTERLEUKIN 7; INTERLEUKIN 7 RECEPTOR; PROTEIN BCL 2;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CELL CYCLE PROGRESSION; CELL INFILTRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DENSITOMETRY; DOWN REGULATION; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; T LYMPHOCYTE; UPREGULATION; XENOTRANSPLANTATION;

ANIMALS; CELL GROWTH PROCESSES; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOWN-REGULATION; HUMANS; INTERLEUKIN-7; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, INTERLEUKIN-7; RNA, MESSENGER; TRANSPLANTATION, HETEROLOGOUS; TUMOR MICROENVIRONMENT; UP-REGULATION;

EID: 79960414811     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-3606     Document Type: Article

References (49)

1. Rich BE, Campos-Torres J, Tepper RI, Moreadith RW, Leder P. Cutaneous lymphoproliferation and lymphomas in interleukin 7 transgenic mice. J Exp Med 1993;177:305-16.
2. Abraham N, Ma MC, Snow JW, Miners MJ, Herndier BG, Goldsmith MA. Haploinsufficiency identifies STAT5 as a modifier of IL-7-induced lymphomas. Oncogene 2005;24:5252-7.
3. Laouar Y, Crispe IN, Flavell RA. Overexpression of IL-7R alpha provides a competitive advantage during early T-cell development. Blood 2004;103:1985-94.
4. Jiang Q, Li WQ, Aiello FB, Mazzucchelli R, Asefa B, Khaled AR. Cell biology of IL-7, a key lymphotrophin. Cytokine Growth Factor Rev 2005;16:513-33.
5. Barata JT, Cardoso AA, Boussiotis VA. Interleukin-7 in T-cell acute lymphoblastic leukemia: an extrinsic factor supporting leukemogenesis? Leuk Lymphoma 2005;46:483-95.
6. Mazzucchelli RI, Warming S, Lawrence SM, Ishii M, Abshari M, Washington AV, et al. Visualization and identification of IL-7 producing cells in reporter mice. PLoS One 2009;4:e7637.
7. Alves NL, Richard-Le Goff O, Huntington ND, Sousa AP, Ribeiro VS, Bordack A, et al. Characterization of the thymic IL-7 niche in vivo. Proc Natl Acad Sci U S A 2009;106:1512-7.
8. Scupoli MT, Vinante F, Krampera M, Vincenzi C, Nadali G, Zampieri F, et al. Thymic epithelial cells promote survival of human T-cell acute lymphoblastic leukemia blasts: the role of interleukin-7. Haematologica 2003;88:1229-37.
9. Scupoli MT, Perbellini O, Krampera M, Vinante F, Cioffi F, Pizzolo G. Interleukin 7 requirement for survival of T-cell acute lymphoblastic leukemia and human thymocytes on bone marrow stroma. Haematologica 2007;92:264-6.
10. Touw I, Pouwels K, van Agthoven T, van Gurp R, Budel L, Hoogerbrugge H, et al. Interleukin-7 is a growth factor of precursor B and T acute lymphoblastic leukemia. Blood 1990;75:2097-101.
11. Barata JT, Keenan TD, Silva A, Nadler LM, Boussiotis VA, Cardoso AA. Common gamma chain-signaling cytokines promote proliferation of T-cell acute lymphoblastic leukemia. Haematologica 2004;89:1459-67.
12. Barata JT, Silva A, Brandao JG, Nadler LM, Cardoso AA, Boussiotis VA. Activation of PI3K is indispensable for interleukin 7-mediated viability, proliferation, glucose use, and growth of T cell acute lymphoblastic leukemia cells. J Exp Med 2004;200:659-69.
13. Barata JT, Cardoso AA, Nadler LM, Boussiotis VA. Interleukin-7 promotes survival and cell cycle progression of T-cell acute lymphoblastic leukemia cells by down-regulating the cyclin-dependent kinase inhibitor p27(kip1). Blood 2001;98:1524-31.
14. Brown VI, Fang J, Alcorn K, Barr R, Kim JM, Wasserman R, et al. Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling. Proc Natl Acad Sci U S A 2003;100:15113-8.
15. Williams RT, Roussel MF, Sherr CJ. Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia. Proc Natl Acad Sci U S A 2006;103:6688-93.
16. +, Arf-null lymphoblastic leukemia. Genes Dev 2007;21:2283-7.
17. Silva A, Yunes JA, Cardoso BA, Martins LR, Jotta PY, Abecasis M, et al. PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability. J Clin Invest 2008;118:3762-74.
18. Barata JT, Boussiotis VA, Yunes JA, Ferrando AA, Moreau LA, Veiga JP, et al. IL-7-dependent human leukemia T-cell line as a valuable tool for drug discovery in T-ALL. Blood 2004;103:1891-900.
19. DSMZ Human and Animal Cell Lines [cited 2011 June 27]. Available from: http://www.dsmz.de/human-and-animal-cell-lines/
20. Amendola M, Venneri MA, Biffi A, Vigna E, Naldini L. Coordinate dualgene transgenesis by lentiviral vectors carrying synthetic bidirectional promoters. Nat Biotechnol 2005;23:108-16.
21. Henriques CM, Rino J, Nibbs RJ, Graham GJ, Barata JT. IL-7 induces rapid clathrin-mediated internalization and JAK3-dependent degradation of IL-7Ralpha in T cells. Blood 2010;115:3269-77.
22. Bene MC, Castoldi G, Knapp W, Ludwig WD, Matutes E, Orfao A, et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia 1995;9:1783-6.
23. Barabe F, Kennedy JA, Hope KJ, Dick JE. Modeling the initiation and progression of human acute leukemia in mice. Science 2007;316:600-4.
24. Johnson SE, Shah N, Panoskaltsis-Mortari A, LeBien TW. Murine and human IL-7 activate STAT5 and induce proliferation of normal human pro-B cells. J Immunol 2005;175:7325-31.
25. Barata JT, Silva A, Abecasis M, Carlesso N, Cumano A, Cardoso AA. Molecular and functional evidence for activity of murine IL-7 on human lymphocytes. Exp Hematol 2006;34:1133-42.
26. Kondo M, Takeshita T, Higuchi M, Nakamura M, Sudo T, Nishikawa S, et al. Functional participation of the IL-2 receptor gamma chain in IL-7 receptor complexes. Science 1994;263:1453-4.
27. Ziegler SE, Morella KK, Anderson D, Kumaki N, Leonard WJ, Cosman D, et al. Reconstitution of a functional interleukin (IL)-7 receptor demonstrates that the IL-2 receptor gamma chain is required for IL-7 signal transduction. Eur J Immunol 1995;25:399-404.
28. Karawajew L, Ruppert V, Wuchter C, Kösser A, Schrappe M, Dörken B, et al. Inhibition of in vitro spontaneous apoptosis by IL-7 correlates with bcl-2 up-regulation, cortical/mature immunophenotype, and better early cytoreduction of childhood T-cell acute lymphoblastic leukemia. Blood 2000;96:297-306.
29. El Kassar N, Lucas PJ, Klug DB, Zamisch M, Merchant M, Bare CV, et al. A dose effect of IL-7 on thymocyte development. Blood 2004;104:1419-27.
30. + T cells. Nat Immunol 2009;10:149-57.
31. Park JH, Yu Q, Erman B, Appelbaum JS, Montoya-Durango D, Grimes HL, et al. Suppression of IL7Ralpha transcription by IL-7 and other prosurvival cytokines: a novel mechanism for maximizing IL-7-dependent T cell survival. Immunity 2004;21:289-302.
32. Cattaruzza L, Gloghini A, Olivo K, Di Francia R, Lorenzon D, De Filippi R, et al. Functional coexpression of Interleukin (IL)-7 and its receptor (IL-7R) on Hodgkin and Reed-Sternberg cells: Involvement of IL-7 in tumor cell growth and microenvironmental interactions of Hodgkin's lymphoma. Int J Cancer 2009;125:1092-101.
33. Nakayama J, Yamamoto M, Hayashi K, Satoh H, Bundo K, Kubo M, et al. BLNK suppresses pre-B-cell leukemogenesis through inhibition of JAK3. Blood 2009;113:1483-92.
34. Armstrong F, Brunet de la Grange P, Gerby B, Rouyez MC, Calvo J, Fontenay M, et al. NOTCH is a key regulator of human T-cell acute leukemia initiating cell activity. Blood 2009;113:1730-40.
35. + T cells from patients with T-cell lineage acute lymphocytic leukemia. Cancer Res 2003;63:6469-77.
36. Qiuping Z, Jie X, Youxin J, Qun W, Wei J, Chun L, et al. Selectively frequent expression of CXCR5 enhances resistance to apoptosis in CD8(+)CD34(+) T cells from patients with T-cell-lineage acute lymphocytic leukemia. Oncogene 2005;24:573-84.
37. -/- mice without affecting peripheral T cell homeostasis. J Immunol 2009;183:7645-55.
38. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
39. Wolfraim LA, Fernandez TM, Mamura M, Fuller WL, Kumar R, Cole DE, et al. Loss of Smad3 in acute T-cell lymphoblastic leukemia. N Engl J Med 2004;351:552-9.
40. Coustan-Smith E, Kitanaka A, Pui CH, McNinch L, Evans WE, Raimondi SC, et al. Clinical relevance of BCL-2 overexpression in childhood acute lymphoblastic leukemia. Blood 1996;87:1140-6.
41. Palomero T, Sulis ML, Cortina M, Real PJ, Barnes K, Ciofani M, et al. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med 2007;13:1203-10.
42. Gutierrez A, Sanda T, Grebliunaite R, Carracedo A, Salmena L, Ahn Y, et al. High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood 2009;114:647-50.
43. Cleaver AL, Beesley AH, Firth MJ, turges NC, O'Leary RA, Hunger SP, et al. Gene-based outcome prediction in multiple cohorts of pediatric T-cell acute lymphoblastic leukemia: a Children's Oncology Group study. Mol Cancer 2010;9:105.
44. McCormack MP, Rabbitts TH. Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2004;350:913-22.
45. Capitini CM, Chisti AA, Mackall CL. Modulating T-cell homeostasis with IL-7: preclinical and clinical studies. J Intern Med 2009;266:141-53.
46. Sportes C, Hakim FT, Memon SA, Zhang H, Chua KS, Brown MR, et al. Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets. J Exp Med 2008;205:1701-14.
47. Sportes C, Babb RR, Krumlauf MC, Hakim FT, Steinberg SM, Chow CK, et al. Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy. Clin Cancer Res 2010;16:727-35.
48. Li B, VanRoey MJ, Jooss K. Recombinant IL-7 enhances the potency of GM-CSF-secreting tumor cell immunotherapy. Clin Immunol 2007;123:155-65.
49. Pellegrini M, Calzascia T, Elford AR, Shahinian A, Lin AE, Dissanayake D, et al. Adjuvant IL-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies. Nat Med 2009;15:528-36.